GlassScriptPhysician profile
Ifeolumipo Sofola
NPI 1578621256
$48,597.30
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $16K · 2021: $5,086 · 2022: $6,635 · 2023: $1,524 · 2024: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Food and Beverage | $167.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $46,581.92 | 2019-2023 | |
| Acclarent, INC | $835.98 | 2019-2022 | |
| Merz North America, INC. | $658.50 | 2019-2021 | |
| Integra Lifesciences Corporation | $143.57 | 2024 | Acclarent Aera |
| Aerin Medical INC. | $125.61 | 2020-2022 | |
| Kaleo, INC. | $85.72 | 2021-2022 | |
| Olympus America INC. | $29.77 | 2019 | |
| Allergan, INC. | $28.39 | 2021 | |
| Abbvie INC. | $23.98 | 2023 | |
| Axogen | $21.93 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.20 | 2019 | |
| Genzyme Corporation | $15.51 | 2022 | |
| Glaxosmithkline, LLC. | $14.41 | 2019 | |
| Checkpoint Surgical, INC | $10.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ifeolumipo Sofola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.